Source link : https://www.newshealth.biz/health-news/europe-approves-its-first-drug-for-von-hippel-lindau-tumors/
The European Medicines Agency (EMA) has recommended that a new oral agent, Welireg (belzutifan), be granted conditional marketing authorization for treatment of two different diseases: the rare genetic disorder von Hippel-Lindau disease (VHL) and a type of advanced renal cell carcinoma often featuring the same gene fault. Welireg represents the first drug treatment for VHL, […]
Author : News Health
Publish date : 2024-12-13 16:26:06
Copyright for syndicated content belongs to the linked Source.